Download PDF
Diabetes aktuell 2022; 20(03): 116-123
DOI: 10.1055/a-1839-8893
Schwerpunkt

Typ-1-Diabetes bei Kindern früh erkennen und präventiv handeln

Die Fr1da-Studie
Peter Achenbach
1   Institut für Diabetesforschung, Helmholtz Zentrum München, Klinikum rechts der Isar, Technische Universität München, München
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Typ-1-Diabetes ist die häufigste chronische Stoffwechselerkrankung im Kindes- und Jugendalter, mit steigenden Inzidenzraten. Die Autoimmunerkrankung kann heute bereits in einem frühen Stadium – noch bevor Symptome auftreten – durch Antikörpertests sicher diagnostiziert werden. Die Fr1da-Studie verfolgt das Ziel, Typ-1-Diabetes bei Kindern im präsymptomatischen Frühstadium zu erkennen, durch Schulung und Monitoring schwere Stoffwechselentgleisungen bei Betroffenen zu verhindern und ihnen die Teilnahme an klinischen Studien mit neuen, potenziell präventiven Therapien zu ermöglichen. Die Durchführbarkeit und der Nutzen eines bevölkerungsweiten Screenings für Typ-1-Diabetes bei Kindern sollen evaluiert werden. Die Aufnahme der Früherkennungsuntersuchung in die medizinische Regelversorgung wird angestrebt.



Publication History

Article published online:
17 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383: 69-82
    CrossrefPubMedGoogle Scholar
  • 2 IDF Diabetes Atlas. 9th. International Diabetes Federation (IDF); 2019 20.04.2020
  • 3 Patterson CC, Karuranga S, Salpea P. et al Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Research and Clinical Practice 2019; 157: 107842
    CrossrefPubMedGoogle Scholar
  • 4 Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371: 1777-1782
    CrossrefPubMedGoogle Scholar
  • 5 Ziegler AG, Bonifacio E. BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012; 55: 1937-1943
    CrossrefPubMedGoogle Scholar
  • 6 Parikka V, Näntö-Salonen K, Saarinen M. et al Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012; 55: 1926-1936
    CrossrefPubMedGoogle Scholar
  • 7 Krischer JP, Lynch KF, Schatz DA. et al The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015; 58: 980-987
    CrossrefPubMedGoogle Scholar
  • 8 Bonifacio E, Achenbach P. Birth and coming of age of islet autoantibodies. Clin Exp Immunol 2019; 198: 294-305
    CrossrefPubMedGoogle Scholar
  • 9 Ziegler AG, Rewers M, Simell O. et al Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479
    CrossrefPubMedGoogle Scholar
  • 10 Insel RA, Dunne JL, Atkinson MA. et al Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38: 1964-1974
    CrossrefPubMedGoogle Scholar
  • 11 American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S14-S31
    CrossrefPubMedGoogle Scholar
  • 12 Rewers A, Dong F, Slover RH. et al Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998–2012. JAMA 2015; 313: 1570-1572
    CrossrefPubMedGoogle Scholar
  • 13 Karges B, Neu A, Hofer S. et al Frequency and influencing factors of ketoacidosis at diabetes onset in children and adolescents--a long-term study between 1995 and 2009. Klinische Pädiatrie 2011; 223: 70-73
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Alonso GT, Coakley A, Pyle L. et al Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017. Diabetes Care 2020; 43: 117-121
    CrossrefPubMedGoogle Scholar
  • 15 Eppens MC, Craig ME, Cusumano J. et al Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006; 29: 1300-1306
    CrossrefPubMedGoogle Scholar
  • 16 Livingstone SJ, Levin D, Looker HC. et al Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 2015; 313: 37-44
    CrossrefPubMedGoogle Scholar
  • 17 Fredheim S, Johannesen J, Johansen A. et al Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA 1c levels. Diabetologia 2013; 56: 995-1003
    CrossrefPubMedGoogle Scholar
  • 18 Cameron FJ, Scratch SE, Nadebaum C. et al Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 2014; 37: 1554-1562
    CrossrefPubMedGoogle Scholar
  • 19 Duca LM, Wang B, Rewers M. et al Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care 2017; 40: 1249-1255
    CrossrefPubMedGoogle Scholar
  • 20 Kovacs M, Finkelstein R, Feinberg TL. et al Initial Psychologic Responses of Parents to the Diagnosis of Insulin-dependent Diabetes Mellitus in Their Children. Diabetes Care 1985; 08: 568-575
    CrossrefPubMedGoogle Scholar
  • 21 Hauenstein EJ, Marvin RS, Snyder AL. et al Stress in Parents of Children With Diabetes Mellitus. Diabetes Care 1989; 12: 18-23
    CrossrefPubMedGoogle Scholar
  • 22 Viner R, McGrath M, Trudinger P. Family stress and metabolic control in diabetes. Arch Dis Child 1996; 74: 418-421
    CrossrefPubMedGoogle Scholar
  • 23 Larsson HE, Vehik K, Bell R. et al Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 2011; 34: 2347-2352
    CrossrefPubMedGoogle Scholar
  • 24 Hekkala AM, Ilonen J, Toppari J. et al Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatric Diabetes 2018; 19: 314-319
    CrossrefPubMedGoogle Scholar
  • 25 Herold KC, Bundy BN, Long SA. et al An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019; 381: 603-613
    CrossrefPubMedGoogle Scholar
  • 26 Quattrin T, Haller MJ, Steck AK. et al Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl J Med 2020; 383: 2007-2017
    CrossrefPubMedGoogle Scholar
  • 27 Sims EK, Bundy BN, Stier K. et al Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13: eabc8980
    CrossrefPubMedGoogle Scholar
  • 28 Raab J, Haupt F, Scholz M. et al Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 2016; 06: e011144
    CrossrefPubMedGoogle Scholar
  • 29 Amoroso M, Achenbach P, Powell M. et al 3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. Clin Chim Acta 2016; 462: 60-64
    CrossrefPubMedGoogle Scholar
  • 30 Ziegler AG, Haupt F, Scholz M. et al 3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technol Ther 2016; 18: 687-693
    CrossrefPubMedGoogle Scholar
  • 31 Liberati D, Wyatt RC, Brigatti C. et al A novel LIPS assay for insulin autoantibodies. Acta Diabetol 2018; 55: 263-270
    CrossrefPubMedGoogle Scholar
  • 32 Ziegler AG, Kick K, Bonifacio E. et al Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA 2020; 323: 339-351
    CrossrefPubMedGoogle Scholar
  • 33 Insel RA, Dunne JL, Ziegler AG. General population screening for type 1 diabetes: has its time come?. Curr Opin Endocrinol Diabetes Obes 2015; 22: 270-276
    CrossrefPubMedGoogle Scholar
  • 34 Hippich M, Holthaus L, Assfalg R. et al A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med (N Y) 2021; 02: 149-163.e4
    Google Scholar
  • 35 Hippich M, Sifft P, Zapardiel-Gonzalo J. et al A public health antibody screening indicates a marked increase of SARS-CoV-2 exposure rate in children during the second wave. Med (N Y) 2021; 02: 571-572
    Google Scholar
  • 36 Segerer H, Wurm M, Grimsmann JM. et al Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence-Incidence and Risk Factors. Dtsch Arztebl Int 2021; 118: 367-372
    CrossrefPubMedGoogle Scholar
  • 37 Kamrath C, Monkemoller K, Biester T. et al Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804
    CrossrefPubMedGoogle Scholar
  • 38 Kick K, Assfalg R, Aydin S. et al Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. Contemporary clinical trials communications 2018; 11: 170-173
    CrossrefPubMedGoogle Scholar
  • 39 Kick K, Hoffmann V, Lange K. et al Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children — evaluation of the Fr1da study. Journal of Public Health 2019; 27: 553-560
    CrossrefGoogle Scholar
  • 40 Karl FM, Winkler C, Ziegler AG. et al Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany. Diabetes Care 2022; 45: 837-844
    CrossrefPubMedGoogle Scholar